PMV Pharmaceuticals (NASDAQ:PMVP) Releases Quarterly Earnings Results

PMV Pharmaceuticals (NASDAQ:PMVP) released its earnings results on Monday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.08), Zacks reports.

PMV Pharmaceuticals Price Performance

PMVP stock opened at $1.32 on Tuesday. PMV Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.26. The business has a 50-day moving average price of $1.43 and a 200 day moving average price of $1.52. The company has a market capitalization of $68.31 million, a P/E ratio of -1.32 and a beta of 1.46.

Analyst Ratings Changes

Separately, Oppenheimer raised PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, PMV Pharmaceuticals currently has an average rating of “Buy” and an average price target of $5.50.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.